Bayer AG projects flat earnings for 2026, citing ongoing liabilities from Roundup-related litigation and declining prices in its crop science segment. The company expects modest growth in pharmaceuticals and consumer health, but structural headwinds are weighing on overall profitability.
- Bayer AG forecasts flat 2026 profits amid ongoing Roundup litigation pressures
- Crop science segment faces 6% year-over-year price decline in 2025
- Pharmaceutical sales expected to grow 1%, consumer health sales up 5%
- €1.3 billion allocated in 2025 for litigation provisions, with similar expectations for 2026
- BAYG.DE shares declined 3.7% on March 4, 2026, amid sector-wide caution
- VIX index rose to 21.4, reflecting heightened market risk sentiment
Bayer AG has issued revised profit guidance for 2026, forecasting earnings to remain flat compared to the prior year. The outlook reflects continued financial strain from unresolved legal claims tied to its glyphosate-based herbicide, Roundup, which have pressured the company’s long-term liabilities and insurance reserves. Despite a projected 1% increase in pharmaceutical sales and a 5% rise in consumer health unit revenue, the agrochemical division is facing persistent downward pressure due to falling crop science product prices, particularly in key markets such as North America and Latin America. The crop science segment, a core component of Bayer’s agricultural business, saw average selling prices decline by approximately 6% year-over-year in the fourth quarter of 2025, according to internal financial disclosures. This trend, coupled with increased regulatory scrutiny and shifting farmer demand toward alternative weed control solutions, is expected to persist into 2026. Meanwhile, the company has allocated €1.3 billion in 2025 specifically for litigation-related provisions, with similar outlays anticipated in 2026. Market participants have reacted cautiously, with Bayer’s shares (BAYG.DE) dropping 3.7% in early trading on March 4, 2026, amid broader sector volatility. The S&P 500’s healthcare and consumer staples indices showed modest declines, while the VIX index (CL=F) rose to 21.4, signaling elevated risk sentiment. Investors are closely monitoring how Bayer’s capital allocation strategy evolves, particularly regarding R&D investments and potential asset divestments. The outlook underscores broader challenges in the agrochemical and pharmaceutical sectors, where legal risk premiums and ESG-related valuation adjustments are increasingly influencing investor behavior. Companies with significant legacy product liabilities may face prolonged earnings volatility unless they achieve meaningful diversification or settlement milestones.